Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Optimism: The Market is Rebounding and Biotech Firms Inspiring News

March 2, 2020 0

The Market Soared Being optimistic about the greatness of American scientific capability does not mean underestimating …

Gilead Sciences To Acquire Forty Seven at $95.50 a Share in Cash

March 2, 2020 0

Gilead Sciences to Acquire Forty Seven Gilead Sciences (GILD) and Forty Seven (FTSV) announced today that the companies …

More About Moderna, Gilead and Forty Seven

February 28, 2020 0

Moderna Therapeutics Among all the firms announcing their interest in working towards designing and producing a …

COVID-19 and the Stock Market

February 27, 2020 0

COVID-19 and the Stock Market The coronavirus that causes COVID-19 is the topic that swallowed all other …

Regeneron and Moderna Are Both Outperforming Today

February 25, 2020 0

Regeneron, Moderna, and COVID-19 The spread of COVID-19, minute creatures that seem to be trying to …

Biotech Stocks Expected to Outperform in Today’s Tumbling Market

February 24, 2020 0

Gilead and Moderna Stocks Will Outperform Today As stated in Prohost Letter #439 Gilead (GILD) investigational …

Prohost Letter #439

February 19, 2020 0

Prohost Letter #439 The Coronavirus Outbreak - COVID-19 The news announced that the coronavirus (now known …

CRISPR Therapeutics and Sisters

February 13, 2020 0

CRISPR, Intellia and Editas CRISPR Therapeutics (CRSP) announced revenues of Q4 2019 that beat analysts’ expectations. …

Cassava Sciences Has Good News from Alzheimer’s Disease Trial. See Also: Theravance Biopharma

February 12, 2020 0

Cassava Sciences From NEWSWIRE we learned that Cassava Sciences (SAVA), a clinical-stage biotechnology company focusing on Alzheimer’s …

Why Moderna Therapeutics’ Stock Is Down Today

February 11, 2020 0

Moderna Therapeutics’ Stock Price Soared, Then Gave Back Its Gains in Two Consecutive Days To begin …

Exelixis Has Good News for Metastatic Castration-Resistant Prostate Cancer

February 11, 2020 0

Exelixis Announced Results from its CABOMETYX® Combination with Roche's TECENTRIQ® News announced by Exelixis (EXEL) about …

Why Regeneron Stock Is Soaring

February 10, 2020 0

Regeneron Pharmaceuticals Stock is Rallying Regeneron Pharmaceuticals (REGN) stock outperformed last week gaining over $27. The …

A Synopsis of Some Biotech Companies’ Events

February 6, 2020 0

Synopsis The way many bloggers are interpreting the quarterly and yearly biotech companies’ financial results seems …

Could Nektar Product NKTR-214 Become a Blockbuster?

February 4, 2020 0

Nektar Therapeutics NKTR-214: A Blockbuster? Nektar Therapeutics (NKTR) published preclinical data of its immuno-oncology candidate NKTR-214 bempegaldesleukin …

In a Market that Seems to Soar Today Our Eyes Are on These Biotech Firms

February 4, 2020 0

As the Market Seems to Soar Our Eyes Are on the Following Biotech Stocks: Amgen (AMGN): A …

Gilead Stock Is Up 4%. See Also: Who Is Developing Prophylactic Vaccines for Coronavirus and Nektar’s News That Moved the Stock Up Over 8%.

February 3, 2020 0

Gilead Stock Is UP Gilead Sciences' (GILD) provided its antiviral experimental drug remdesivir to physicians for …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Optimism: The Market is Rebounding and Biotech Firms Inspiring News

Gilead Sciences To Acquire Forty Seven at $95.50 a Share in Cash

More About Moderna, Gilead and Forty Seven

COVID-19 and the Stock Market

Regeneron and Moderna Are Both Outperforming Today

Biotech Stocks Expected to Outperform in Today’s Tumbling Market

Prohost Letter #439

CRISPR Therapeutics and Sisters

Cassava Sciences Has Good News from Alzheimer’s Disease Trial. See Also: Theravance Biopharma

Why Moderna Therapeutics’ Stock Is Down Today

Exelixis Has Good News for Metastatic Castration-Resistant Prostate Cancer

Why Regeneron Stock Is Soaring

A Synopsis of Some Biotech Companies’ Events

Could Nektar Product NKTR-214 Become a Blockbuster?

In a Market that Seems to Soar Today Our Eyes Are on These Biotech Firms

Gilead Stock Is Up 4%. See Also: Who Is Developing Prophylactic Vaccines for Coronavirus and Nektar’s News That Moved the Stock Up Over 8%.

Vertex Beats Expectations in 2019 and Promises a Bright Future

Regenxbio, Moderna Therapeutics and Other Biotech Stocks Posted Gains in a Bad Market Day

Compugen

The European Medicine Agency Validates the Gilead Application for a CAR T Product for Mantle Cell Lymphoma